NCI Issues 2025 AGM Notice; Key Votes on Profit Distribution, Auditor Re-appointment and Director Remuneration

Bulletin Express
05/27

New China Life Insurance Company Ltd. (NCI) will convene its 2025 Annual General Meeting (AGM) on 26 June 2026 at 2:30 p.m. in Beijing (21/F, NCI Tower, A12 Jianguomenwai Avenue, Chaoyang District). The meeting will adopt a registered-poll format, with on-site voting for all shareholders and an online option for A-share investors.

Key resolutions to be tabled include: • Approval of the Board Report, Directors’ Performance Report and Independent Non-executive Directors’ Performance Report for FY 2025. • Endorsement of the 2025 Annual Report (A-share and H-share versions). • Approval of the 2025 profit-distribution plan; if passed, the final dividend will be distributed on 7 Aug 2026 to H-shareholders on record as of 17 Jul 2026. • Re-appointment of the Company’s accounting firms for FY 2026. • Adoption of new Administrative Measures on the Remuneration of Directors and Senior Management.

Shareholder schedule: • 22 Jun 2026 (16:30 HKT): Deadline to lodge H-share transfer documents to qualify for AGM attendance and voting. • 23 – 26 Jun 2026: H-share register closed for AGM record-date determination (record date: 23 Jun 2026). • 13 Jul 2026 (16:30 HKT): Deadline to lodge H-share transfers to qualify for the 2025 final dividend. • 14 – 17 Jul 2026: H-share register closed for dividend entitlement (record date: 17 Jul 2026).

Proxy arrangements require submission of completed forms to Computershare Hong Kong Investor Services by 25 Jun 2026 (24 hours before the AGM). Joint shareholders’ voting will follow the seniority order on the register.

The Board will also present a report for review on the company’s 2025 related-party transactions. The AGM is expected to last half a day, with attendees responsible for their own travel and accommodation costs.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10